Citrine Global Corp Stock Price, News & Analysis

Citrine Global Corp. (CTGL) has signed a memorandum of understanding (MOU) with MyPlant Bio Ltd. to acquire 55% of its shares for USD 2.44 million. This acquisition aligns with Citrine Global's strategy to lead in plant-based wellness and pharma solutions, leveraging MyPlant’s expertise in botanical drug development. The collaboration aims to enhance Citrine's product lines with scientifically backed formulations, tapping into the growing markets projected to reach USD 625 billion (nutritional supplements) and USD 53 billion (plant-derived drugs) by 2030 and 2026, respectively.

Citrine Global Corp. (OTCQB: CTGL) has filed a provisional patent application for compositions and methods aimed at mitigating side effects from medicinal treatments, aging, and unhealthy lifestyles. The patent, No: 63/418,046, focuses on solutions to common side effects like dryness, headaches, and fatigue. Additionally, the company has announced the launch of the GreenFeels^TM product lines, which include over 100 wellness products and nutritional supplements designed to enhance quality of life. The launch emphasizes plant-based solutions and targets both U.S. and global markets.

Citrine Global Corp. (OTCQB: CTGL) announced that its subsidiary, Cannovation Center Israel Ltd, has filed a provisional patent application with the USPTO. The application focuses on alleviating oral cavity side effects related to medications and unhealthy lifestyles. With over 25% of the population experiencing dry mouth, the company aims to develop plant-based wellness solutions, including their SmokLy™ sprays. Citrine Global's strategy revolves around innovative plant-based products, emphasizing infrastructure for production and sales across North America and Europe.

Citrine Global Corp. (OTCQB: CTGL) announced the appointment of Prof. Itamar Grotto to its Board of Directors and as President of Green Vision Center Israel. Prof. Grotto, a seasoned expert in public health, aims to advance the company's strategy in developing innovative plant-based wellness and pharma solutions. The company has acquired 125,000 square feet of land in southern Israel to establish the Green Vision Center, which will serve as a hub for production and innovation in the plant-based sector. This development is expected to enhance the company's infrastructure and market presence.

Citrine Global Corp. (OTCQB: CTGL), a leader in plant-based wellness solutions, recently shared a Letter to Shareholders from CEO Ora Elharar-Soffer. The company reports significant milestones since its acquisition, including the launch of the Green Side by Side product line in Q1 2022 and the acquisition of a 125,000 sq ft site for its Green Vision Center in Israel. Citrine aims to address common side effects of medications through innovative products and plans to uplist to Nasdaq, positioning itself for transformative growth in the wellness and pharma markets, expected to reach $625 billion by 2030.

Citrine Global Corp. (OTCQB: CTGL) announced the acquisition of 11,687 sqm of industrial land in Yeruham, Israel, to establish the Green Vision Center. This center aims to focus on botanical solutions, including medicinal cannabis and natural wellness products. Approximately 90% of the land acquisition costs are funded by Israeli government grants and tax incentives. The Green Vision Center will feature state-of-the-art manufacturing, research, and development facilities, furthering Citrine's mission to enhance global health through innovative wellness solutions.

Citrine Global Corp.'s subsidiary, Cannovation Center Israel Ltd., has launched its 'Green Side by Side' product line aimed at medical cannabis patients. This line features natural formulations, including oral sprays and capsules, and is marketed in collaboration with Intelicanna Ltd. in Israel. This initiative is part of Cannovation's strategy to address the increasing need for solutions to side effects from cannabis treatment, as the medical cannabis market is projected to surge to $46 billion by 2026. The company is also building a Cannovation Center for product innovation in Israel.

Citrine Global (CTGL) announced the filing of a provisional patent application for a method to treat side effects associated with cannabis use. The invention targets medical cannabis patients who often face adverse effects, with studies indicating 15% discontinue treatment despite its benefits. The medical cannabis market is expected to grow from $16 billion in 2021 to $46 billion by 2026. Citrine has developed the Green Botanicals product line to complement cannabis therapies and aims to market these supplements through established cannabis distribution channels.

Citrine Global (OTCQB: CTGL) has announced a manufacturing agreement between its subsidiary, Cannovation Center Israel Ltd., and iBOT Israel-Botanicals Ltd., to launch a new line of herbal products and supplements branded as Green Botanicals. This product line will include various herbal formulas, with plans for clinical trials on select items. The distribution strategy focuses on pharmacies and medical cannabis channels. iBOT's facility meets stringent health certifications, ensuring quality manufacturing.